Strong intellectual property (IP) protection laws.
Highly trained workforce, stable government and economy.
Favourable tax climate for foreign investment.
World-class capabilities across the entire value chain, from basic research to support
services.
Well-established research infrastructure backed by strong supporting industries.
Strong government support for drug discovery, as illustrated by the new biomedical
research centre Biopolis.
Traditional preference for prescription and branded medicines.
Local manufacturing sector output comprises predominantly cheap, basic medicines.
Small generics segment due to traditional preference for branded products, despite
government encouragement and generic substitution in public hospitals.
Problematic access to research and development (R&D) venture finance.
Small population size, which limits longer-term market potential.
Tendering system reflects negatively on overall pharmaceutical values.
Government focused on developing Singapore into a hub for pharmaceuticals,medical devices, clinical trials and biotechnology, attracting both foreign investment
and patients.
ブランド製品が伝統的に好まれているため、政府の奨励や、公共病院でのノーブランド品の代用があるにも関わらず、ノーブランド部門は小規模である。
研究開発(R&D)を行うベンチャー・ファイナンスとの、問題ある結びつき方。
長期市場の可能性を制限する、小規模な人口。
売買同時入札方式が、薬学の実用性全体に悪影響を及ぼす。
政府は、シンガポールを、海外投資や患者を引き付ける、薬学、医療装置、臨床実験や生体工学の中枢へと発展させることに焦点を置いている。
Pro-reform government policy adding impetus to domestic market development in
search of foreign investment.
ASEAN harmonisation gradually removing trade barriers.
Increasing potential of export sector, boosted by multinational presence and the
country’s growing status as a regional R&D and manufacturing base.
Better import-export balance, allowing greater re-investment in market development in
medium and long term.
Tax breaks offered to drug makers in exchange for increase in local production
capacity.
Expansion of the elderly and disabled care programme to boost demand for
treatments of chronic diseases.
Recent government proposals to reduce price levels in the country pose a threat to
investment.
Patent expirations on leading products threatening overall values.
Possible expansion of parallel trade and greater collaboration between the public and
private sectors as cost-containment measures would depress margins.
Growing regional competition for multinational investment from Taiwan, South Korea
and others, including India and China.
@kinenaoto
評価ありがとうございます。